SHA68 is a selective antagonist for the chemokine receptor CXCR2, making it a valuable tool in research focused on inflammatory processes. It is primarily used to study the role of CXCR2 in conditions involving neutrophil migration, such as acute lung injury, arthritis, and other inflammatory diseases. By blocking CXCR2 signaling, SHA68 helps reduce the infiltration of neutrophils into tissues, allowing researchers to assess the impact of this pathway on disease progression. It has also been applied in cancer research, where CXCR2 is implicated in tumor growth and angiogenesis, particularly in models of melanoma and lung cancer. Due to its specificity, SHA68 is widely used in preclinical studies to validate CXCR2 as a therapeutic target without affecting the closely related receptor CXCR1, supporting the development of more targeted anti-inflammatory and anti-cancer drugs.